Biologic drug is a product that contain components of living organisms such as animal, human, or produced from living organisms. Antibodies, vaccines, and interleukins are some examples of biologic drugs. Furthermore, biologic drugs are administrated by injection or infusion, as biologic products can easily lose their potency due to acid present in the stomach, if administered by oral route to the patient. Moreover, biologic drug for cancer treatment helps to increase the body’s ability to fight against various types of cancers such as nasopharyngeal cancer, prostate cancer, breast cancer, neck cancer, and lung cancer. Pembrolizumab, Atezolizumab, Cemiplimab-rwlc, Blinatumomab and Durvalumab are few examples of biologic drugs that are used for the treatment of cancer.

Global Cancer Biologics Market Drivers

The global cancer biologics market is expected to witness significant growth over the forecast period, owing to increasing approvals of biologic drug by regulatory authorities for the treatment of cancer. For instance, in 2018, the U.S Food and Drug Administration (FDA) approved blinatumomab, for the patient suffering from B-cell precursor acute lymphoblastic leukemia, which show reduction in the severity of the disease, as the minimal residual disease (MRD) is found to be greater than or equal to 0.1%. Furthermore, in 2018, U.S FDA approved Cemiplimab-rwlc, for the treatment metastatic advanced stage cutaneous squamous cell cancer. The recommended Cemiplimab-rwlc dose for the patient is 350 mg, which is administrated as intravenous infusion over 30 minutes, in every three weeks.

Moreover, in January 2020, F. Hoffmann-La Roche AG announced about its submission of supplemental biological license to U.S Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) drug for most common form of liver cancer. Therefore, increasing number of regulatory approvals of biologic drug for the treatment of cancer, is expected to boost of cancer biologics market growth over the forecast period.

Global Cancer Biologics Market Restraints

However, high cost associated with cancer biologic drug is one of the major restraint that is expected to hamper the global cancer biologics market growth. For instance, cost of blinatumomab is US$ 17,800 per year. Furthermore, side effects associated with cancer biologic drug such as allergic reactions, injection site reactions, weakness, diarrhea, nausea, vomiting, and rash yet remains another factor hindering the global cancer biologics market growth.

Global Cancer Biologics Market Regional Analysis

North America is expected to account for highest market share in the global cancer biologics market, owing to increasing prevalence of cancer, among people in North America. For instance, in 2019, in the U.S, according to the American Cancer Society’s (ACS), around 1,762,450 new cancer cases were diagnosed, and 606,880 new cancer deaths were reported.

Furthermore, increasing drug approvals for the treatment of metastatic merkel cell carcinoma (MCC) by the company is one of the factors that is driving the global cancer biologic market growth. For instance, in 2018, pembrolizumab received approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients suffering from metastatic Merkel cell carcinoma (MCC).

Europe is expected to account for second highest market share in the global cancer biologics market, owing to increasing prevalence of cancer in Europe region. For instance, in 2018, around 3.9 million of cancer with new cases excluding non-melanoma skin cancer, and 1.9 million death from cancer were reported by the International Agency for Research on Cancer (IARC), in collaboration with the European Network of Cancer Registries (ENCR, as well as the European Commission’s Joint Research Centre (JRC).

Moreover, Asia Pacific is expected to exhibit CAGR over the forecast period due to the increasing approval of drugs by regulatory bodies for the treatment of Hodgkin's disease (blood cancer) by the company. For instance, in 2018, National Medical Products Administration (NMPA) of China approved Sintilimab injection, which is sold under the brand name Tyvyt, and was jointly announced by Innovent Biologics, Inc. and Eli Lilly and Company. Sintilimab injection is used for the treatment of Hodgkin's disease (blood cancer), and is fully human IgG4 monoclonal antibody.

Global Cancer Biologics Market Key Players

Key players operating in the global cancer biologic market are Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Sanofi S.A., Bayer AG, EnGeneIC Ltd, and GlaxoSmithKline PLC.

Market Taxonomy:

On the basis of product, the global cancer biologics market is segmented into:

Monoclonal Antibodies
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
- Chemo labeled Antibodies
- Radiolabeled Antibodies
- Bispecific Monoclonal Antibodies
Cytokine-Based Immunotherapy
Cancer Vaccines
Treatment Vaccines
Preventive Vaccines
CAR-T Cell Therapy
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
PD-1 & PD-L1 Checkpoint Inhibitor